Identification
- Summary
Clofedanol is an antitussive used for the symptomatic relief of acute cough caused by minor throat and bronchial irritation.
- Brand Names
- Biclora, Poly Hist Pd, Vanacof-8
- Generic Name
- Clofedanol
- DrugBank Accession Number
- DB04837
- Background
Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
Structure for Clofedanol (DB04837)
- Weight
- Average: 289.8
Monoisotopic: 289.123341974 - Chemical Formula
- C17H20ClNO
- Synonyms
- Chlophedianol
- Clofedanol
- Clofedanolum
- Clofedianolo
Pharmacology
- Indication
Used in the treatment of dry cough.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Cough ••• ••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Chlophedianol (or Clofedanol) is a centrally-acting cough suppressant. It has local anesthetic and antihistamine properties, and may have anticholinergic effects at high doses.
- Mechanism of action
Suppresses the cough reflex by a direct effect on the cough center in the medulla of the brain.
Target Actions Organism AHistamine H1 receptor antagonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Hepatic.
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmphetamine Amphetamine may decrease the sedative activities of Clofedanol. Benzphetamine Benzphetamine may decrease the sedative activities of Clofedanol. Benzylpenicilloyl polylysine Clofedanol may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Clofedanol. Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Clofedanol. - Food Interactions
- Avoid alcohol.
- Take with or without food. The absorption is unaffected by food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Chlophedianol hydrochloride 69QQ58998Y 511-13-7 XYGSFNHCFFAJPO-UHFFFAOYSA-N Clofedanol hydrochloride Not Available Not Available Not applicable - International/Other Brands
- Antitussin
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ulone Syrup 25 mg / 5 mL Oral Bausch & Lomb Inc 1962-12-31 Not applicable Canada 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Abanatuss Ped Chlophedianol hydrochloride (25 mg/5mL) + Dexchlorpheniramine maleate (2 mg/5mL) + Pseudoephedrine hydrochloride (60 mg/5mL) Solution Oral KRAMER NOVIS 2015-07-01 Not applicable US 
Abanatuss Ped Drops Chlophedianol hydrochloride (6.25 mg/1mL) + Dexchlorpheniramine maleate (0.5 mg/1mL) + Pseudoephedrine hydrochloride (15 mg/1mL) Solution Oral KRAMER NOVIS 2015-08-05 Not applicable US Atuss Da Chlophedianol hydrochloride (12.5 mg/5mL) + Brompheniramine maleate (2 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL) Liquid Oral Aber Pharmaceuticals, Llc 2016-02-08 2018-01-31 US Atuss Da Chlophedianol hydrochloride (12.5 mg/5mL) + Brompheniramine maleate (2 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL) Liquid Oral Carwin Associates, Inc 2016-10-25 Not applicable US Atuss Da Chlophedianol hydrochloride (12.5 mg/5mL) + Brompheniramine maleate (2 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL) Liquid Oral Magna Pharmceuticals, Inc. 2018-11-20 Not applicable US
Categories
- ATC Codes
- R05DB10 — Clofedanol
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Chlorobenzenes / Aralkylamines / Aryl chlorides / Tertiary alcohols / 1,3-aminoalcohols / Trialkylamines / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- 1,3-aminoalcohol / Alcohol / Amine / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Chlorobenzene / Diphenylmethane
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 42C50P12AP
- CAS number
- 791-35-5
- InChI Key
- WRCHFMBCVFFYEQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3
- IUPAC Name
- 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol
- SMILES
- CN(C)CCC(O)(C1=CC=CC=C1)C1=CC=CC=C1Cl
References
- Synthesis Reference
Lorenz, R., Gosswald, R. and Henecka, H.; US. Patent 3,031,377; April 24, 1962; assigned to Farbenfabriken Bayer AG, Germany.
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015585
- PubChem Compound
- 2795
- PubChem Substance
- 46505324
- ChemSpider
- 2693
- 21254
- ChEBI
- 135207
- ChEMBL
- CHEMBL1201313
- Therapeutic Targets Database
- DAP001080
- PharmGKB
- PA164748134
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Clofedanol
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Oral Suspension Oral Tablet, multilayer Oral Tablet Oral Liquid Oral Tablet, chewable Oral Syrup Oral Solution / drops Oral Syrup Oral 25 mg / 5 mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 120 °C PhysProp - Predicted Properties
Property Value Source Water Solubility 0.0621 mg/mL ALOGPS logP 3.51 ALOGPS logP 3.46 Chemaxon logS -3.7 ALOGPS pKa (Strongest Acidic) 13.18 Chemaxon pKa (Strongest Basic) 8.87 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 23.47 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 84.94 m3·mol-1 Chemaxon Polarizability 31.54 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9892 Blood Brain Barrier + 0.9474 Caco-2 permeable + 0.7603 P-glycoprotein substrate Substrate 0.6468 P-glycoprotein inhibitor I Non-inhibitor 0.6719 P-glycoprotein inhibitor II Non-inhibitor 0.8383 Renal organic cation transporter Inhibitor 0.5846 CYP450 2C9 substrate Non-substrate 0.7596 CYP450 2D6 substrate Substrate 0.619 CYP450 3A4 substrate Substrate 0.754 CYP450 1A2 substrate Non-inhibitor 0.5972 CYP450 2C9 inhibitor Non-inhibitor 0.8098 CYP450 2D6 inhibitor Inhibitor 0.8482 CYP450 2C19 inhibitor Non-inhibitor 0.7196 CYP450 3A4 inhibitor Non-inhibitor 0.6746 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6213 Ames test Non AMES toxic 0.8129 Carcinogenicity Non-carcinogens 0.7042 Biodegradation Not ready biodegradable 0.9928 Rat acute toxicity 2.7383 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.755 hERG inhibition (predictor II) Inhibitor 0.7948
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 173.6594304 predictedDarkChem Lite v0.1.0 [M-H]- 159.37625 predictedDeepCCS 1.0 (2019) [M+H]+ 173.5771304 predictedDarkChem Lite v0.1.0 [M+H]+ 161.73424 predictedDeepCCS 1.0 (2019) [M+Na]+ 173.7843304 predictedDarkChem Lite v0.1.0 [M+Na]+ 167.82741 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Maurer H, Pfleger K: Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J Chromatogr. 1988 Aug 19;430(1):31-41. [Article]
Drug created at September 26, 2007 14:12 / Updated at February 02, 2024 22:54